Free Newsletter
NYT article considers Bristol-Myers strategy
The Bristol-Myers Squibb's "String of Pearls" initiative to buy small biotech companies, as well as the rights to market or develop drugs from other companies, might not be the best strategy for the company, according to an article in today's New York Times.
In fact, the company's earnings report indicates that its specialization on drugs for Alzheimer disease, cancer and hepatitis C might not be enough to help it overcome lost revenues when some major drugs go off patent over the next few years.
Drugs like Abilify, Avapro and Plavix have been bringing Bristol-Myers big bucks, but the company might just be suited for a merger or takeover in the current climate.
Still, reported earnings of $1.2 billion were respectable, and ahead of forecasts, for now at least.
- see the New York Times story
Related Articles:
Bristol-Myers will layoff yet another 10%
Execs talk deals, diversification and downturn
Bristol looks to free up $1B in cash
ZymoGenetics scores mega-deal with BMS
BMS to pay Exelixis $240M for cancer drugs
Rumor mill: BMS positioning itself for sale
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: